Z Orthop Unfall 2020; 158(S 01): S234
DOI: 10.1055/s-0040-1717582
Vortrag
DKOU20-1083 Allgemeine Themen->23. Tumorchirurgie

APO 10 and TKTL1 - reliable markers for the detection and follow-up sarcomas?

F Traub
*   präsentierender Autor
1   Z. Orthopädie und Unfallchirurgie Universitätsmedizin Mainz, Universitätsklinik für Orthopädie Tübingen, Mainz
,
S Schleicher
2   Orthopädische Universitätsklinik Tübingen, Tübingen
,
S Sachsenmaier
2   Orthopädische Universitätsklinik Tübingen, Tübingen
› Institutsangaben
 
 

    Objectives In clinical practice, tumor markers are used in primary diagnostics, for staging or follow-up in several carcinomas. Some of these markers have prognostic potential and some have high sensitivity and specificity. Up to date neither for soft-tissue nor bone sarcomas, such markers have been established. This pilot study aimed to evaluate whether an EDIM test (epitope detection in macrophages) of Apo10 and TKTL1

    could be a reliable test for the follow-up of soft-tissue and bone sarcomas.

    Methods The EDIM test is based on two biomarkers Apo10 and TKTL1. Apo10 is an epitope of DNaseX (deoxyribonuclease X), which plays a role in apoptosis. It accumulates in tumor cells and is associated with apoptosis resistance and increased proliferation. TKTL1 (transketolase like 1) on the other hand plays a crucial role in the anaerobic glycolysis of tumor cells. It has been shown that increased lactate production leads to basal lamina destruction and is associated with increased metastasis. The aim of this pilot study was to evaluate whether an EDIM test for Apo10 and TKTL1 is suitable for the aftercare of soft tissue and bone sarcoma.

    Results and Conclusion In total, blood samples from 75 patients with a high-grade (stage III) bone or soft-tissue sarcomas could be included. The mean age of all patients was 58.9 years (14-88). 35 of the patients were male. All

    patients had an increased EDIM-Apo10 as well as a elevated TKTL1 score before biopsy. After completion of the therapy, the values in the follow-up controls normalized. In an independent control group of healthy volunteers, only normal values were measured.

    Conclusion: All patients with high-grade sarcoma had an increased EDIM-Apo10 and TKTL1 score. After successful curative therapy, the values normalize. We believe that this approach could to be very useful technique for follow-up monitoring. Further work is being undertaken with a larger cohort.

    Stichwörter -


    #

    Publikationsverlauf

    Artikel online veröffentlicht:
    15. Oktober 2020

    © 2020. Thieme. All rights reserved.

    Georg Thieme Verlag KG
    Rüdigerstraße 14, 70469 Stuttgart, Germany